← All trials
NCT05510843
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 6, 2022
- Primary completion
- Mar 31, 2023
- Completion date
- Sep 30, 2023
- First posted
- Aug 22, 2022
- Last posted
- Dec 22, 2022
- Enrollment
- 5
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Third Harmonic Bio, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.